Subject: PR tied to their EU partner
https://www.esperion.com/news-...

“This real-world study adds to the body of clinical evidence and further underscores the therapeutic role for bempedoic acid in helping patients achieve their LDL-C goals, which is particularly important as cardiovascular disease remains the number one cause of death in Europe and the United States,” said Sheldon Koenig, President and CEO of Esperion. “We are very pleased with DSE’s continued progress and look at successes in the growing adoption of bempedoic acid in Europe and other international markets as a potential proxy for the significant market opportunity in the United States.”

Dreamer